{
"id":"mk19_b_rm_t09",
"number":9,
"bookId":"rm",
"title":{
"__html":"Nonbiologic Disease-Modifying Antirheumatic Drugs"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"3e1c2d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t09"
}
]
},
"Nonbiologic Disease-Modifying Antirheumatic Drugs"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"744605",
"class":"col hd l",
"children":[
"Agent"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da0b90",
"class":"col hd l",
"children":[
"Mechanisms of Action"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b670b8",
"class":"col hd l",
"children":[
"Indications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"55422e",
"class":"col hd l",
"children":[
"Common Monitoring Parameters"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98cff",
"class":"cell txt l",
"children":[
"Methotrexate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e1ed49",
"class":"cell txt l",
"children":[
"Low dose: anti-inflammatory agent via up-regulation of adenosine A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2A"
]
},
" signaling"
]
},
" ",
{
"type":"p",
"hlId":"22c181",
"class":"cell txt l",
"children":[
"High dose: antimetabolite/folate antagonist used in neoplastic disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edfadf",
"class":"cell txt l",
"children":[
"RA; psoriasis; psoriatic arthritis; IBD; SLE (arthritis only); reactive arthritis; DM; PM; vasculitis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"925a29",
"class":"cell txt l",
"children":[
"Baseline: chest radiography, hepatitis screening, CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"3e9749",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine after first month, then approximately every 2-3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"476428",
"class":"cell txt l",
"children":[
"Hydroxychloroquine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70dd49",
"class":"cell txt l",
"children":[
"Uncertain; appears to involve stabilization of lysosomal vacuoles, leading to inhibition of antigen processing and/or inhibition of Toll-like receptor activation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"effc9e",
"class":"cell txt l",
"children":[
"SLE; RA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"f20e1e",
"class":"cell txt l",
"children":[
"Retinal examinations at baseline and annual examination after 5 years of therapy to evaluate for retinopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"121888",
"class":"cell txt l",
"children":[
"Sulfasalazine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"80e60e",
"class":"cell txt l",
"children":[
"Unknown; the prodrug is broken down into 5-amino salicylic acid (active metabolite in gastrointestinal tract) and sulfapyridine (exerts systemic action)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a446db",
"class":"cell txt l",
"children":[
"RA; SpA; IBD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"fa1ad7",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 3-6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14a480",
"class":"cell txt l",
"children":[
"Leflunomide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f457d",
"class":"cell txt l",
"children":[
"Inhibits mitochondrial enzyme dihydroorotate dehydrogenase to block pyrimidine synthesis (decreasing lymphocyte production); antiproliferative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dbacce",
"class":"cell txt l",
"children":[
"RA; psoriatic arthritis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"21f6b4",
"class":"cell txt l",
"children":[
"Baseline: hepatitis screening, CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"391423",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine after 4 weeks, then every 3 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ac0373",
"class":"cell txt l",
"children":[
"Azathioprine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34b681",
"class":"cell txt l",
"children":[
"Prodrug of 6-mercaptopurine; purine analogue; inhibits DNA synthesis essential for proliferating T and B lymphocytes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8cf71",
"class":"cell txt l",
"children":[
"SLE; DM; PM; vasculitis; IBD"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"cece88",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ce44b",
"class":"cell txt l",
"children":[
"Cyclophosphamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"797df4",
"class":"cell txt l",
"children":[
"Alkylating agent; blocks DNA synthesis and causes cell death, especially of T cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfc49e",
"class":"cell txt l",
"children":[
"Severe and life-threatening complications in SLE, DM, PM, and vasculitis; may be used when other agents fail"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b1e05",
"class":"cell txt l",
"children":[
"Close monitoring clinically and measuring CBC, chemistries, LCTs, urinalysis every 4-8 weeks"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31de20",
"class":"cell txt l",
"children":[
"Mycophenolate mofetil"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f8969b",
"class":"cell txt l",
"children":[
"Active metabolite (mycophenolic acid) inhibits purine synthesis; preferentially inhibits T and B lymphocytes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dc5b81",
"class":"cell txt l",
"children":[
"SLE (especially lupus nephritis); vasculitis (maintenance therapy); DM; PM; SSc"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"76a311",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine after 4 weeks and then every 3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"955334",
"class":"cell txt l",
"children":[
"Cyclosporine, voclosporin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a74ad",
"class":"cell txt l",
"children":[
"Inhibit calcineurin (transcription activating factor); preferentially target T cells"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97ae39",
"class":"cell txt l",
"children":[
"SLE; psoriasis; RA (cyclosporine)"
]
},
" ",
{
"type":"p",
"hlId":"f8060b",
"class":"cell txt l",
"children":[
"Lupus nephritis (voclosporin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"730871",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine"
]
},
" ",
{
"type":"p",
"hlId":"33a9ef",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 2-3 months",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f5702",
"class":"cell txt l",
"children":[
"Tofacitinib, baricitinib, upadacitinib"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d70c2d",
"class":"cell txt l",
"children":[
"Janus kinase inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b113c",
"class":"cell txt l",
"children":[
"RA (tofacitinib, baricitinib, upadacitinib)"
]
},
" ",
{
"type":"p",
"hlId":"917415",
"class":"cell txt l",
"children":[
"Psoriatic arthritis (tofacitinib)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cbd82",
"class":"cell txt l",
"children":[
"Baseline: CBC, LCTs, serum creatinine, lipid panel"
]
},
" ",
{
"type":"p",
"hlId":"58bedd",
"class":"cell txt l",
"children":[
"Thereafter: CBC, LCTs, serum creatinine every 8 weeks, lipids after 8 weeks and then every 6 months"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1b7af",
"class":"cell txt l",
"children":[
"Apremilast"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c5790",
"class":"cell txt l",
"children":[
"Phosphodiesterase-4 inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"35ad78",
"class":"cell txt l",
"children":[
"Psoriasis; psoriatic arthritis; oral ulcers associated with Beh√ßet syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9ffa1",
"class":"cell txt l",
"children":[
"Baseline: weight"
]
},
" ",
{
"type":"p",
"hlId":"1abc6d",
"class":"cell txt l",
"children":[
"Thereafter: weight, neuropsychiatric effects"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CBC = complete blood count; DM = dermatomyositis; IBD = inflammatory bowel disease; LCT = liver chemistry test; PM = polymyositis; RA = rheumatoid arthritis; SLE = systemic lupus erythematosus; SpA = spondyloarthritis; SSc = systemic sclerosis."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Recommended monitoring interval is for a stable dose but may be shorter after initiation or in the case of abnormal results; must be individualized to the patient's risk for toxicity."
]
]
}